Recent Updates
Recently added Catalysts
KNSA Positive Sentiment Score: 68/100

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Wednesday, August 28, 2024 1 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc has announced its participation in the 2024 Wells Fargo Healthcare Conference scheduled for September 4, 2024. Management will engage in a fireside chat during the event, accessible via a live webcast on the company's website. Kiniksa focuses on developing medicines for patients with significant unmet medical needs, with promising immune-modulating assets under its portfolio.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kiniksa Pharmaceuticals is participating in a prestigious healthcare conference.
  • The company is focused on addressing significant unmet medical needs.
  • Their therapeutic assets target underserved cardiovascular and autoimmune conditions.

Full Press Release Details

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor Contact
Jonathan Kirshenbaum
jkirshenbaum@kiniksa.com
Kiniksa Media Contact

Frequently Asked Questions

When will Kiniksa participate in the Wells Fargo Healthcare Conference?

Kiniksa will participate on September 4, 2024, at 8:00 a.m. Eastern Time.

How can I watch Kiniksa's presentation live?

The live webcast can be accessed on Kiniksa’s Investors & Media webpage.

Will there be a replay of Kiniksa's event?

Yes, a replay will be available on Kiniksa’s website within 48 hours post-event.

What is the focus of Kiniksa Pharmaceuticals?

Kiniksa focuses on developing therapeutic medicines for serious diseases with unmet needs.

What are Kiniksa's key immune-modulating assets?

Kiniksa’s key assets include ARCALYST®, abiprubart, and mavrilimumab.

Tags: KNSA Viatris Investor Conferences Healthcare Kiniksa Pharmaceuticals healthcare conference ARCALYST therapeutic medicines
Last updated: Aug 28, 2024